Drugs

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Photo taken from Matthew Goetz/LinkedIn

Apr 29, 2024, 14:18

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:

Is the benefit of Abemacicib compromised in those that require dose reductions?

A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.

Clinicians should utilize dose modifications when necessary to maximize adherence.”

Matthew Goetz

Additional information.
Source: Matthew Goetz/LinkedIn

Abemacicib Ashwin Shahir Breast Cancer cancer Hope S. Rugo Irfan Cicin Jens Huober Joyce O'Shaughnessy Laura Testa Matthew Goetz Mayo Clinic Miguel Martin monarchE Nadia Harbeck OncoDaily Oncology Priya Rastogi Ran Wei Sara M. Tolaney Stephen R. D. Johnston Valentina Guarneri Valérie André

ASCO GI 2025 - Everything You Need To Know About Biggest Gastrointestinal cancer Symposium

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Special Coverage